Endovascular management of acute stroke.

IF 98.4 1区 医学 Q1 MEDICINE, GENERAL & INTERNAL The Lancet Pub Date : 2024-09-28 DOI:10.1016/S0140-6736(24)01410-7
Thanh N Nguyen, Mohamad Abdalkader, Urs Fischer, Zhongming Qiu, Simon Nagel, Hui-Sheng Chen, Zhongrong Miao, Pooja Khatri
{"title":"Endovascular management of acute stroke.","authors":"Thanh N Nguyen, Mohamad Abdalkader, Urs Fischer, Zhongming Qiu, Simon Nagel, Hui-Sheng Chen, Zhongrong Miao, Pooja Khatri","doi":"10.1016/S0140-6736(24)01410-7","DOIUrl":null,"url":null,"abstract":"<p><p>Stroke related to large vessel occlusion is a leading cause of disability and death worldwide. Advances in endovascular therapy to reopen occluded arteries have been shown to reduce patient disability and mortality. Expanded indications to treat patients with large vessel occlusion in the late window (>6 h from symptom onset), with basilar artery occlusion, and with large ischaemic core at presentation have enabled treatment of more patients with simplified imaging methods. Ongoing knowledge gaps include an understanding of which patients with large ischaemic infarct are more likely to benefit from endovascular therapy, the role of endovascular therapy in patients who present with low National Institutes of Health Stroke Scale scores or medium or distal vessel occlusion, and optimal management of patients with underlying intracranial atherosclerotic disease. As reperfusion can now be facilitated by intravenous thrombolysis, mechanical thrombectomy, or both, the development of cytoprotective or adjunctive drugs to slow infarct growth, enhance reperfusion, or decrease haemorrhagic risk has gained renewed interest with the hope to improve patient outcomes.</p>","PeriodicalId":18014,"journal":{"name":"The Lancet","volume":"404 10459","pages":"1265-1278"},"PeriodicalIF":98.4000,"publicationDate":"2024-09-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"The Lancet","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1016/S0140-6736(24)01410-7","RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"MEDICINE, GENERAL & INTERNAL","Score":null,"Total":0}
引用次数: 0

Abstract

Stroke related to large vessel occlusion is a leading cause of disability and death worldwide. Advances in endovascular therapy to reopen occluded arteries have been shown to reduce patient disability and mortality. Expanded indications to treat patients with large vessel occlusion in the late window (>6 h from symptom onset), with basilar artery occlusion, and with large ischaemic core at presentation have enabled treatment of more patients with simplified imaging methods. Ongoing knowledge gaps include an understanding of which patients with large ischaemic infarct are more likely to benefit from endovascular therapy, the role of endovascular therapy in patients who present with low National Institutes of Health Stroke Scale scores or medium or distal vessel occlusion, and optimal management of patients with underlying intracranial atherosclerotic disease. As reperfusion can now be facilitated by intravenous thrombolysis, mechanical thrombectomy, or both, the development of cytoprotective or adjunctive drugs to slow infarct growth, enhance reperfusion, or decrease haemorrhagic risk has gained renewed interest with the hope to improve patient outcomes.

查看原文
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
急性中风的血管内治疗。
与大血管闭塞有关的中风是全球致残和致死的主要原因。事实证明,通过血管内治疗重新开通闭塞动脉可降低患者的致残率和死亡率。对晚期窗口期(症状出现后 6 小时以上)大血管闭塞患者、基底动脉闭塞患者和发病时有大面积缺血核心的患者扩大了治疗适应症,使更多患者能够通过简化的成像方法得到治疗。目前的知识空白包括:了解哪些大面积缺血性脑梗死患者更有可能从血管内治疗中获益;血管内治疗在美国国立卫生研究院卒中量表评分较低、中远端血管闭塞患者中的作用;以及对有潜在颅内动脉粥样硬化疾病的患者进行最佳治疗。由于现在可以通过静脉溶栓、机械取栓或两者兼用来促进再灌注,因此开发细胞保护药物或辅助药物来减缓梗塞生长、加强再灌注或降低出血风险的研究再次受到关注,希望能改善患者的预后。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 去求助
来源期刊
The Lancet
The Lancet 医学-医学:内科
CiteScore
148.10
自引率
0.70%
发文量
2220
审稿时长
3 months
期刊介绍: The Lancet is a world-leading source of clinical, public health, and global health knowledge. It was founded in 1823 by Thomas Wakley and has been an independent, international weekly general medical journal since then. The journal has an Impact Factor of 168.9, ranking first among 167 general and internal medicine journals globally. It also has a Scopus CiteScore of 133·2, ranking it second among 830 general medicine journals. The Lancet's mission is to make science widely available to serve and transform society, positively impacting people's lives. Throughout its history, The Lancet has been dedicated to addressing urgent topics, initiating debate, providing context for scientific research, and influencing decision makers worldwide.
期刊最新文献
Non-communicable diseases: can implementation research change the game for policy and practice? Priorities for sickle cell disease global research and implementation. Addressing global gun violence: a Lancet Commission on Global Gun Violence and Health. Changing the culture of blood culture. The time to address the antibiotic pipeline and access crisis is now.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1